Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Svetlana Hamm

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Handbook of Experimental Pharmacology|December 12, 2007
TLR9-mediated recognition of DNAThomas Müller, Svetlana Hamm, Stefan Bauer
Advances in Experimental Medicine and Biology|October 6, 2009
Pattern recognition by Toll-like receptorsStefan Bauer, Thomas Müller, Svetlana Hamm
Journal of Immunotoxicology|October 24, 2009
Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonistsSvetlana Hamm, Sandra Rath, Susanne Michel, et al.
Immunobiology|April 15, 2008
Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9Stefan Bauer, Stephanie Pigisch, Doris Hangel, et al.
Plos One|December 11, 2013
A novel microtubule inhibitor 4SC-207 with anti-proliferative activity in taxane-resistant cellsElena Bausch, Hella Kohlhof, Svetlana Hamm, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2007
TLR9 contributes to antiviral immunity during gammaherpesvirus infectionSimone Guggemoos, Doris Hangel, Svetlana Hamm, et al.
Scientific Reports|May 6, 2021
Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinomaGundula Streubel, Sabine Schrepfer, Hannah Kallus, et al.
Immunobiology|October 27, 2009
Alternating 2'-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonistSvetlana Hamm, Eicke Latz, Doris Hangel, et al.
International Immunology|February 10, 2007
Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivoSvetlana Hamm, Antje Heit, Martina Koffler, et al.
Journal for Immunotherapy of Cancer|November 10, 2019
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Handbook of Experimental Pharmacology|December 12, 2007
TLR9-mediated recognition of DNAThomas Müller, Svetlana Hamm, Stefan Bauer
Advances in Experimental Medicine and Biology|October 6, 2009
Pattern recognition by Toll-like receptorsStefan Bauer, Thomas Müller, Svetlana Hamm
Journal of Immunotoxicology|October 24, 2009
Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonistsSvetlana Hamm, Sandra Rath, Susanne Michel, et al.
Immunobiology|April 15, 2008
Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9Stefan Bauer, Stephanie Pigisch, Doris Hangel, et al.
Plos One|December 11, 2013
A novel microtubule inhibitor 4SC-207 with anti-proliferative activity in taxane-resistant cellsElena Bausch, Hella Kohlhof, Svetlana Hamm, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2007
TLR9 contributes to antiviral immunity during gammaherpesvirus infectionSimone Guggemoos, Doris Hangel, Svetlana Hamm, et al.
Scientific Reports|May 6, 2021
Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinomaGundula Streubel, Sabine Schrepfer, Hannah Kallus, et al.
Immunobiology|October 27, 2009
Alternating 2'-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonistSvetlana Hamm, Eicke Latz, Doris Hangel, et al.
International Immunology|February 10, 2007
Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivoSvetlana Hamm, Antje Heit, Martina Koffler, et al.
Journal for Immunotherapy of Cancer|November 10, 2019
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler, et al.
Pageof 2